Theravance Biopharma Inc cash flow to debt ratio of 315.96% indicates that the company generates enough cash to cover a substantial portion of its debt. This level indicates very strong financial health.

Theravance Biopharma Inc's free cash flow has increased -2.11K% from $-11.87M last year to $238.50M, signaling increasing performance

Theravance Biopharma Inc's debt to equity ratio is 0.06, which means that the company's assets are healthy financed, signaling financial stability.

Theravance Biopharma Inc's debt has decreased relative to shareholder equity from 0.28 last year to 0.06 today, signaling strengthened financials

Theravance Biopharma Inc has a net cash position, so leverage is healthy.

Theravance Biopharma Inc's interest coverage ratio is -4.73, which means that the company struggles to meet interest obligations, signaling financial risk.

Theravance Biopharma Inc's profit margin has increased (-158.86%) in the last year from -87.63% to 51.58%, signaling increasing performance

Theravance Biopharma Inc's short-term assets of $418.46M exceed its short-term liabilities of $38.30M

Theravance Biopharma Inc's return on assets of 11.45% is higher than the 5.00% threshold, indicating efficient asset utilization

Theravance Biopharma Inc's return on equity of 16.69%, is higher than 15.00%, indicating good performance

Theravance Biopharma Inc's operating cash flow exceeds its net income, indicating high-quality earnings backed by actual cash generation

Theravance Biopharma Inc had positive net income in only 2 out of 5 years, indicating unstable earnings

Theravance Biopharma Inc has positive free cash flow, indicating the company generates cash after capital expenditures

Theravance Biopharma Inc has a free cash flow yield of 27.21%, which is above the 2.00% threshold, indicating strong cash generation relative to market value

Theravance Biopharma Inc's yearly earnings has increased -287.70% since last year from $-56.42M to $105.89M, signaling increasing performance

Theravance Biopharma Inc's yearly revenue has increased 66.92% since last year from $64.38M to $107.46M, signaling increasing performance

ROIC -1.07% (Source: FMP key-metrics). Below the 5% partial-credit threshold. Score: 0 of 2. The 5% and 10% cutoffs anchor to typical US weighted-average cost of capital. Below 5% indicates the company is not generating returns above its likely cost of capital under this definition of invested capital. Invested capital here includes equity, non-current liabilities (pension obligations, deferred taxes, lease obligations), and short-term debt. Cash is not subtracted. Companies with substantial float, lease portfolios, or cash holdings will score lower under this definition than under narrower operating-capital definitions. See methodology.

Theravance Biopharma Inc's 3-year revenue CAGR of 27.91% is positive, indicating growing revenue over the past 3 years

Theravance Biopharma Inc had revenue growth in 3 out of 5 years, indicating consistent revenue performance

Theravance Biopharma Inc had positive ROE in only 2 out of 5 years, indicating inconsistent returns on equity

Theravance Biopharma Inc has insufficient data to evaluate this check.

Theravance Biopharma Inc has an earnings yield of 5.93%, which is above the 4.00% threshold, indicating the stock offers reasonable value relative to its earnings

Theravance Biopharma Inc is overvalued relative to its fair value price of 0.75 based on EBITDA multiple model

Theravance Biopharma Inc has an EV/EBITDA ratio of 4.64x, which is below the 20.00x threshold, indicating reasonable valuation relative to its operating earnings

Theravance Biopharma Inc is overvalued relative to its fair value price of -39.41 based on Earnings Fair Value model

Theravance Biopharma Inc had non-positive diluted EPS five years ago; the PEG ratio is not meaningful and the check fails.

Theravance Biopharma Inc has a price-to-book ratio of 3.13x, which is below the 5.00x threshold, indicating reasonable valuation relative to its book value

Theravance Biopharma Inc has a price-to-sales ratio of 8.69x, which exceeds the 8.00x threshold, indicating the stock may be overvalued relative to its revenue